<DOC>
	<DOCNO>NCT00973037</DOCNO>
	<brief_summary>The purpose study investigate impact CYP2D6 Genotype clinical effect tamoxifen use sample prospective randomize multicenter study ( ASTRRA ) .</brief_summary>
	<brief_title>CYP2D6 Genotype Clinical Effect Tamoxifen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>The patient must sign informed consent form . The patient must sign informed consent genotype screen test . The patient must 18 year old 45 year old make decision independently . Patients must undergo excision primary breast mass , proven histologically invasive breast adenocarcinoma . ( The type mastectomy perform , number axillary node remove , number axillary node find positive , tumor size must include CRFs . For patient one discrete tumor mass measure report CRFs . ) Patients must within 3 month last cycle chemotherapy . Patients must history normal menstruation prior start chemotherapy . Stage I , II III Woman , less equal 45 year age The test result estrogen receptor positive . WHO performance status 0 , 1 2 . Patients treat cytotoxic chemotherapy pre post surgery . Permissible prior chemotherapy ; currently locally available approved standard chemotherapy adjuvant neoadjuvant setting : e.g. , AC ( Doxorubicin/cyclophosphamide ) follow taxane , AC ( Doxorubicin/cyclophosphamide ) , TA ( Docetaxel/ Doxorubicin ) , FAC ( 5fluorouracil/ doxorubicin / cyclophosphamide ) others . Adequate hematological function define hemoglobin 10g/dl , neutrophil count 1.5 X 10 9/L platelet 100 X 10 9/L . Adequate hepatic function define AST ALT 2.5 X upper limit normal . Alkaline phosphatase 5 X upper limit normal , unless bone metastasis absence liver disease . Renal function adequate define creatinine &lt; 175 mmol/L . The test result estrogen receptor negative unknown . Patients history hysterectomy oophorectomy . Sarcomas squamous cell carcinoma breast eligible . Patients malignancy ( breast cancer ) within last 5 year , except adequately treat situ carcinoma cervix basal cell/squamous cell carcinoma skin . Investigational drug give within previous 4 week . Patients thrombocytopenia ( platelet &lt; 100 X 10 9/L anticoagulant therapy ( contraindicate due risk bleed i.m . injection Zoladex ) . Patients treat CMF ( cyclophosphamide/methotrexate/5fluorouracil ) prior chemotherapy . Patients pregnant lactate ineligible .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Breast neoplasm</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Genotype</keyword>
	<keyword>CYP2D6</keyword>
</DOC>